18 results about "Medications therapy" patented technology

A mobile computing device for providing medication therapy recommendations includes a secure execution environment having one or more services executing therein. One service of the one or more services is configured to establish a secure user interaction process at the mobile computing device. The mobile computing device includes a normal execution environment having a medication therapy application executing therein. The medication therapy application is configured to determine at least one medication delivery instruction, request confirmation of the delivery instruction using the secure user interaction process, and provide certified medication delivery instructions to a communications interface configured for communication with a medication delivery unit responsive to a confirmation result. The confirmation result is received, at least in part, responsive to the secure user interaction process.

A computer-implemented method of estimating a risk associated with patient safety is disclosed. One or more computers execute processing comprising receiving a training data set comprising drug-associated patient safety data and human omics data. One or more probabilistic features from the training data set are identified, where the one or more probabilistic features comprise human omics features associated with a drug therapeutic. A ground truth label associated with the drug therapeutic and comprising a positive or a negative patient safety outcome corresponding to the one or more probabilistic features is derived. The method trains one or more machine learning models in accordance with the ground truth label and applies the trained machine learning models to a patient dataset of human omics data to generate a calculated indication of a positive or a negative patient safety outcome. The method takes one or more actions in response to the calculated indication.

The present invention relates to drugs, dosage regimens, dosing intervals, and methods of administration for treating antibody-mediated rejection using an effective amount of a drug targeting Blys and / or APRIL. The result shows that the provided effective dose of the drug targeting Blys and / or APRIL shows good safety and treatment effect in the process of preventing, treating or relieving antibody-mediated rejection in patients who are about to accept, are receiving or have accepted entity organ transplantation.

The tubular catheter wall of the catheter (1) comprises a random skeleton (7) having a micromachined cutting pattern (7A), the overall skeleton resection rate being between 40% and 90%. A random skeleton (7) arranged between the inner liner and the outer laminate comprises a plurality of mutually connected struts (21L-28L, 31L-38L, 21R-28R, 31R-38R). Each strut has a respective pair of two mutually opposed longitudinal strut edges (41, 42). Each strut edge (41, 42) has a random bend and / or a random tip, which makes each strut unique. Randomly shaped skeleton strut edges not only improve the mutual bonding among the skeleton, the liner and the outer laminate, but also improve the torsionality of the conduit, including the prevention of the occurrence of whip phenomena during twisting.

A system and method of applying therapy to a patient includes navigating a dual lumen catheter to a desired segment of bronchus; inflating, via a first tube of the dual lumen catheter, a balloon located on a distal portion of the catheter to isolate the segment bronchial tube; injecting a therapeutic medium into the isolated segment bronchial tube via a second tube of the dual lumen catheter; and retracting the dual lumen catheter to leave the balloon indwelling, where the balloon retains the injected therapeutic medium in the isolated segment bronchial tube.

The application discloses application of a substance with increased OSKM content or activity in preventing joint cartilage aging and treating osteoarthritis diseases. The OSKM of the application is obtained by connecting Oct4, Sox2, Klf4 and C-Myc. The experiment of the application proves that the OSKM or the substance with increased OSKM content or activity has a definite effect in preventing joint cartilage aging and treating osteoarthritis diseases, the application provides a new strategy for developing gene therapy for preventing joint cartilage aging and treating osteoarthritis diseases, and expands the selectable range of clinical gene therapy and drug therapy.

The invention belongs to the technical field of biological medicines, and particularly relates to a long-acting non-insulin dependent double-target recombinant protein and application thereof in diabetes treatment. According to the present invention, the double-target recombinant protein is obtained by connecting the polypeptide of the targeted activation beta-Klotho / FGFR1c compound with the polypeptide of the targeted activation GLP-1 receptor through the linker; the double-target recombinant protein provided by the invention has a hypoglycemic effect, reduces the inflammation level of diabetes mellitus, effectively improves the blood sugar of diabetes mellitus, and can be used as a drug for treating and / or preventing diabetes mellitus and related diseases, protecting the structural integrity of liver cells of diabetes mellitus and reversing liver injury related to diabetes mellitus; the double-target recombinant protein provided by the invention is independent in hypoglycemic mechanism, different from insulin and non-insulin dependent hypoglycemic mechanism.

The invention relates generally to medication therapy and more particularly to a system and methods for medication therapy management to support improved adherence and alert clinicians of changes in behavior or symptoms. The system may facilitate interactions between various data sources (e.g., medical health records, genomics databases, and other connected third-party devices) to manage workflow, execute rules, interface with knowledge bases, codify information, schedule events, provide notification, and more. In addition, the system may include a conversational or actionable artificial intelligence persona tailored to each user and configured to, for example, converse, instruct, and / or coach a user according to one or more features of the system. Advantageously, the system may improve adherence and facilitate patient engagement, care transition, and disease management, resulting in, for example, reduced healthcare costs for providers and payers, and enhanced drug use for pharmaceutical manufacturers, pharmacies, and specialty pharmacies.

A system for mimicking cellular microenvironment is provided and includes a chip, a hydrogel, and cells in contact with the hydrogel. The chip includes a first carrier having a pore and a second carrier coupled to the first carrier. The hydrogel is disposed in the pore and includes extracellular matrix. Also provided is a method for evaluating cell development, including providing the system for mimicking cellular microenvironment; providing a stimulation to a responsive hydrogel; and evaluating the cell development. Further provided is a method for evaluating drug therapy effectiveness, including providing the system for mimicking cellular microenvironment; administering the drug to the cells; and evaluating drug therapy effectiveness.

The invention provides a construction method and application of a spontaneous esophageal precancerous lesion or esophageal cancer non-human animal model. The spontaneous esophageal precancerous lesion or esophageal cancer non-human animal model is obtained through expression deletion of Trp53 and Cdkn2a of a non-human animal. The non-human animal model prepared by the invention can be used as an ideal animal model for screening drug candidates, evaluating drug treatment effects, evaluating drug toxicological effects and researching esophageal precancerous lesions or pathogenesis of esophageal cancer.

The present application relates to the technical field of gene drug therapy, and in particular to an application of ACSS2 protein in diabetic nephropathy and a gene drug; the application includes: using ACSS2 protein with expression levels lower than normal as a biomarker for diabetic nephropathy; the gene drug includes overexpressed ACSS2 protein and / or an adeno-associated virus vector and an adeno-associated virus for overexpressing a target gene of the ACSS2 protein; based on a large number of experimental findings, ACSS2 protein may be a potential therapeutic target for diabetic nephropathy. Based on the characteristics of this discovery, it is clarified that the kidneys can be directly protected by reversing the gene expression imbalance caused by the disease. Therefore, overexpression of ACSS2 protein mediated by adeno-associated virus can achieve improvement of diabetic nephropathy through gene therapy, thereby filling the gap in the existing technology for the application of ACSS2 protein in diabetic nephropathy.

The invention provides temperature-sensitive PAD4 inhibitor loaded hydrogel as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The temperature-sensitive type PAD4 inhibitor loaded hydrogel provided by the invention comprises a temperature-sensitive type hydrogel matrix and a PAD4 inhibitor loaded in the temperature-sensitive type hydrogel matrix, the temperature-sensitive type hydrogel matrix is prepared from the following components: chitosan and beta-glycerophosphate disodium; the PAD4 inhibitor has a structure as shown in a formula 1. The PAD4 inhibitor is loaded in the hydrogel, and the PAD4 inhibitor is slowly released through local application, so that formation of NETs is inhibited for a long time, chronic inflammation is relieved, and finally the healing process of diabetic wounds is accelerated. The temperature-sensitive PAD4 inhibitor loaded hydrogel provided by the invention shows a remarkable treatment effect in experiments, and overcomes the limitation of traditional drug treatment to a certain extent.

A software program application that elicits, collects, corrects, and records patient responses to illness-diagnosis, prescribed medical-treatment, and anatomical and other relevant health-elements matching scenarios presented in crossword, scrolling matching, scrolling-capture, adventure-construction, adventure-capture, ballistic-target (shooter), and other video game formats, without-or-with virtual reality and without-or-with avatars is provided. Game application criteria for success may be based on diagnostic, prescribed medication / management, and optional anatomical or other related information that the application imports securely in compliance with HIPAA requirements from the Patient-Player's web health portal.

The invention provides an immortalized cell strain of human carotid globular paraganglioma, and in the SDHD gene, c.6Agt; the invention relates to a 178182delAAGGC (Alkali AAGGC). The invention also provides an immortalized cell strain of the human carotid artery globular paranglioma, and the preservation number of the immortalized cell strain is CGMCC (China General Microbiological Culture Collection Center) NO.45756. The invention also provides an application of the immortalized cell strain of the human carotid paraganglioma. The gene sequencing result of the immortalized cell line shows that the SDHD gene mutation site (EO3 exon c.178182delAAGGC) exists in the immortalized cell line. The tumor cell line is a cell strain derived from human carotid artery globular paraganglioma, and the discovery of the cell strain contributes to the basic research and drug therapy of the carotid artery globular paraganglioma at present.

A mobile computing device for providing medication therapy recommendations includes a secure execution environment having one or more services executing therein. One service of the one or more services is configured to establish a secure user interaction process at the mobile computing device. The mobile computing device includes a normal execution environment having a medication therapy application executing therein. The medication therapy application is configured to determine at least one medication delivery instruction, request confirmation of the delivery instruction using the secure user interaction process, and provide certified medication delivery instructions to a communications interface configured for communication with a medication delivery unit responsive to a confirmation result. The confirmation result is received, at least in part, responsive to the secure user interaction process.

A system and method for monitoring and delivering medication to a patient includes a controller that has a control algorithm and a closed loop control that monitors the control algorithm. A sensor is in communication with the controller and monitors a medical condition. A rule base application in the controller receives data from the sensor and the closed loop control and compares the data to predetermined medical information to determine the risk of automation of therapy to the patient. The controller then provides a predetermined risk threshold where below the predetermined risk threshold automated closed loop medication therapy is provided. If the predetermined risk threshold is met or exceeded, automated therapy adjustments may not occur and user / clinician intervention is requested.

The present invention provides a device and method for monitoring patients during the administration of prescription therapeutic drugs that require monitoring for safety and efficacy and are known to have consciousness-altering effects. [Solution] A system for monitoring a patient during a consciousness alteration therapy drug treatment session, comprising a data collection module that electronically communicates with a network server to store data in a non-temporary computer-readable medium in order to monitor the patient's health status during and after the treatment session.